A Phase II Study for the efficacy and safety of Erlotinib for Patients previously treated Non-small cell Lung Cancer Patients with EGFR Mutations
Phase 2
Recruiting
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000003215
- Lead Sponsor
- Fujita Health Universty Hospital Division of Respirology and Allergology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 28
Inclusion Criteria
Not provided
Exclusion Criteria
1)Active infection (fever) 2)Cases with past history of EGFR-TKI 3)Presence of active interstitial lung disease or pulmonary fibrosis 4)Patients with massive pleural or prericardial effusion or ascites 5)Patients with uncontrollable complications 6)Patients with active double cancer 7)Pregnancy or lactation. 8)Patients whose participation in the trial is judged to be inappropriate by the attending doctor.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method rseponse rate
- Secondary Outcome Measures
Name Time Method Evaluation of safety, Progression free survival, Median survival time